Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: Comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions

International Journal of Pharmaceutics

Volumn 375, Issue 1-2, 2009, Pages 48-54

  Hassan, Hazem E ^a,b   Mercer, Susan L ^a   Cunningham, Christopher W ^a   Coop, Andrew ^a   Eddington, Natalie D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Ein Helwan   (Egypt)

Author keywords

Opioids; P glycoprotein; Transporters

Indexed keywords

6 DESOXYMORPHINE; ADENOSINE TRIPHOSPHATASE; CODEINE; ETORPHINE; GLYCOPROTEIN P; METHYL THEVINOL; MORPHINE; MORPHINE DERIVATIVE; N 2 METHYLPROPYL NORMEPERIDINE; N ALLYL NORMEPERIDINE; N BENZYL NORMEPERIDINE; N BENZYLCODEINE; N BUTYL NORMEPERIDINE; N CROTYL NORMEPERIDINE; N METHYLALLYL NORMEPERIDINE; N PHENYLBUTYL NORMEPERIDINE; N PHENYLPROPYL NORMEPERIDINE; N PROPYL NORMEPERIDINE; NALOXONE; NALTREXONE; NORPETHIDINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OXYMORPHONE; PETHIDINE; PETHIDINE DERIVATIVE; PIPERIDINE DERIVATIVE; THEVINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG TOLERANCE; ENZYME ACTIVITY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MEPERIDINE; MICE; MICE, KNOCKOUT; MORPHINE DERIVATIVES; P-GLYCOPROTEINS; PAIN; PAIN MEASUREMENT;

EID: 67349278541     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.03.037     Document Type: Article

References (41)

1. Aquilante C.L., Letrent S.P., Pollack G.M., and Brouwer K.L. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 66 (2000) PL47-PL51
2. Beaver W.T., Wallenstein S.L., Houde R.W., and Rogers A. Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J. Clin. Pharmacol. 17 (1977) 186-198
3. Bentley K.W., Hardy D.G., and Meek B. Novel analgesics and molecular rearrangements in the morphine-thebaine group. II. Alcohols derived from 6,14-endo-etheno- and 6,14-endo-ethanotetrahydrothebaine. J. Am. Chem. Soc. 89 (1967) 3273-3280
4. Callaghan R., and Riordan J.R. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 268 (1993) 16059-16064
5. Casy A., and Parfitt R. Opioid Analgesics: Chemistry and Receptors (1986), Plenum Press, New York
6. Chen C., and Pollack G.M. Enhanced antinociception of the model opioid peptide [d-penicillamine] enkephalin by P-glycoprotein modulation. Pharm. Res. 16 (1999) 296-301
7. D'amour F., and Smith D. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72 (1941) 74-79
8. Dagenais C., Graff C.L., and Pollack G.M. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol. 67 (2004) 269-276
9. Glare P.A., and Walsh T.D. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J. Clin. Oncol. 11 (1993) 973-978
10. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 (1993) 385-427
11. Hassan, H.E., Myers, A.L., Coop, A., Eddington, N.D., 2009, April 15. Differential Involvement of P-glycoprotein (Abcb1) in permeability, tissue distribution and antinociceptive activity of methadone, buprenorphine and diprenorphine: in vitro and in vivo evaluation. J. Pharm. Sci., (Epub ahead of print).
12. Hassan H.E., Myers A.L., Lee I.J., Coop A., and Eddington N.D. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J. Pharm. Sci. 96 (2007) 2494-2506
13. Hoffmaster K.A., Zamek-Gliszczynski M.J., Pollack G.M., and Brouwer K.L. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J. Pharmacol. Exp. Ther. 311 (2004) 1203-1210
14. Iijima I., Minamikawa J., Jacobson A.E., Brossi A., and Rice K.C. Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone. J. Med. Chem. 21 (1978) 398-400
15. Janssen P.A., and Eddy N.B. Compounds related to pethidine-IV. New general chemical methods of increasing the analgesic activity of pethidine. J. Med. Pharm. Chem. 2 (1960) 31-45
16. Jette L., Beaulieu E., Leclerc J.M., and Beliveau R. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol. 270 (1996) F756-765
17. Kalvass J.C., Graff C.L., and Pollack G.M. Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice. Pharm. Res. 21 (2004) 1867-1870
18. Koczka K., and Bernath G. Preparation of codeine derivatives, stereoisomeric with reference to the nitrogen atom (1958), Chemistry and Industry, London, UK p. 1401
19. Letrent S.P., Pollack G.M., Brouwer K.R., and Brouwer K.L. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 15 (1998) 599-605
20. Letrent S.P., Pollack G.M., Brouwer K.R., and Brouwer K.L. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 27 (1999) 827-834
21. Letrent S.P., Polli J.W., Humphreys J.E., Pollack G.M., Brouwer K.R., and Brouwer K.L. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem. Pharmacol. 58 (1999) 951-957
22. Lin J.H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55 (2003) 53-81
23. Lin J.H., and Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42 (2003) 59-98
24. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., and Polli J.W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303 (2002) 1029-1037
25. Mercer S.L., Hassan H.E., Cunningham C.W., Eddington N.D., and Coop A. Opioids and efflux transporters. Part 1: P-Glycoprotein substrate activity of N-substituted analogs of meperidine. Bioorg. Med. Chem. Lett. 17 (2007) 1160-1162
26. Nielsen C.K., Ross F.B., and Smith M.T. Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J. Pharmacol. Exp. Ther. 295 (2000) 91-99
27. Orahovats P.D., Winter C.A., Lehman E.G., and Flataker L. Comparative studies of 6-substituted delta 6-desoxymorphines and morphine with special reference to 6-methyl-delta6-desoxymorphine. J. Pharmacol. Exp. Ther. 114 (1955) 100-109
28. Pastan I., and Gottesman M.M. Multidrug resistance. Annu. Rev. Med. 42 (1991) 277-286
29. Polli J.E., Rekhi G.S., Augsburger L.L., and Shah V.P. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J. Pharm. Sci. 86 (1997) 690-700
30. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., and Serabjit-Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299 (2001) 620-628
31. Rapoport H., and Bonner R. Δ7 and Δ8-desoxycodeine. J. Am. Chem. Soc. 73 (1951) 2872-2876
32. Reden J., Reich M.F., Rice K.C., Jacobson A.E., Brossi A., Streaty R.A., and Klee W.A. Deoxymorphines: role of the phenolic hydroxyl in antinociception and opiate receptor interactions. J. Med. Chem. 22 (1979) 256-259
33. Ross F.B., Wallis S.C., and Smith M.T. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain 84 (2000) 421-428
34. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97 (1996) 2517-2524
35. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., and Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96 (1995) 1698-1705
36. Skarke C., Jarrar M., Schmidt H., Kauert G., Langer M., Geisslinger G., and Lotsch J. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13 (2003) 651-660
37. Thompson S.J., Koszdin K., and Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92 (2000) 1392-1399
38. Thorgeirsson S.S., Silverman J.A., Gant T.W., and Marino P.A. Multidrug resistance gene family and chemical carcinogens. Pharmacol. Ther. 49 (1991) 283-292
39. Umans J.G., and Inturrisi C.E. Antinociceptive activity and toxicity of meperidine and normeperidine in mice. J. Pharmacol. Exp. Ther. 223 (1982) 203-206
40. Wandel C., Kim R., Wood M., and Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96 (2002) 913-920
41. Zong J., and Pollack G.M. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm. Res. 17 (2000) 749-753